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Abstract
Transforming growth factor-b1 (TGF-b1) is an important mediator of atrial fibrosis and atrial fibrillation (AF). But the involved
genetic mechanism is unknown. Herein, the TGF-b1 C-509T polymorphism (rs1800469) was genotyped in a case-control
study of 840 patients and 845 controls in Chinese population to explore the association between the polymorphism and
susceptibility and prognosis of lone AF. As a result, the CT and/or TT genotypes had an increased lone AF risk [adjusted odds
ratio (OR) = 1.50 for CT, OR = 3.72 for TT, and OR= 2.15 for CT/TT], compared with the TGF-b1CC genotype. Moreover,
patients carrying CT/TT genotypes showed a higher possibility of AF recurrence after catheter ablation, compared with
patients carrying CC genotype. In a genotype-phenotype correlation analysis using 24 normal left atrial appendage samples,
increasing gradients of atrial TGF-b1 expression levels positively correlated with atrial collagen volume fraction were
identified in samples with CC, CT and TT genotypes. The in vitro luciferase assays also showed a higher luciferase activity of
the -509T allele than that of the -509C allele. In conclusion, the TGF-b1 C-509T polymorphism is involved in the etiology of
lone AF and thus may be a marker for genetic susceptibility to lone AF and predicting prognosis after catheter ablation in
Chinese populations. Therefore, we provide new information about treatment strategies and our understanding of TGF-b1
in AF.
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Introduction
Atrial fibrillation (AF), the most common cardiac arrhythmia, is
associated with increased morbidity, mortality and cost [1]. To
date, the precise mechanism of AF remains largely unknown. It is
particularly true for patients with lone AF (LAF), which is AF in
the absence of heart disease or comorbidities predisposing to the
arrhythmia. However, increasing evidence showed that the atrial
fibrosis is essential for the development and progression of AF [2–
3].
It is accepted that transforming growth factor-b1 (TGF-b1) is
the most powerful profibrotic factor, stimulating the secretion of
collagen into the extracellular matrix by fibroblasts [4]. Over-
expression of TGF-b1 selectively induced atrial fibrosis, leading to
increased conduction heterogeneity and AF vulnerability without
affecting the cellular electrophysiology [5]. Inhibition of TGF-b1
expression by Tranilast significantly reduced the atrial fibrosis, as a
result, reduced conduction abnormalities and AF vulnerability
were observed [6]. These studies suggest that TGF-b1 plays an
essential role in inducing AF.
In the human TGF-b1 gene, three polymorphisms in the
promoter are presently known [7]. It was proposed in a previous
in vitro study that the differences in the induced expression and
production of TGF-b1 were a consequence of genetic sequence
polymorphisms in the regulatory promoter region [8]. Neverthe-
less, in Chinese and other Asians, the genetic polymorphism in the
promoter was detected only in -509 [9–10]. Therefore, we
hypothesized that the TGF-b1 C-509T polymorphism was
associated with LAF risk and AF recurrence after catheter ablation
in Chinese population. Furthermore, we also designed to explore
whether this polymorphism had an effect on TGF-b1 expression
in vitro and left atrial appendage (LAA) tissue.
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Materials and Methods
2.1. Ethics statement
This hospital-based case-control study was approved by the
Review Boards of the Affiliated Drum Tower Hospital of Nanjing
University Medical School and the First Affiliated Hospital of
Nanjing Medical University (2007-NJEA-10). All subjects provided
written informed consent to be included in the study. The study
was conducted according to the Helsinki Declaration and
approved by the ethics committees of the respective institutions
(2007-NJEA-10). We have complied with the World Medical
Association Declaration of Helsinki regarding ethical conduct of
research involving human subjects.
2.2. Study Subjects
We consecutively recruited 2786 non-valvular AF patients
between October 2007 and June 2013. Each patient donated 5 ml
venous blood upon admission to the hospital and was interviewed
to collect demographic data and clinical information. Among
them, a total of 860 patients were diagnosed as lone AF, which was
based on the following criteria [11]: age at first diagnosis of AF ,
60 years, no past cardiovascular history, no evidence suggesting
ischemic heart disease, no cardiomyopathy, no heart failure, no
valvular heart disease, no diabetes, no hypertension within two
years of the onset of AF, no hyperthyroidism. Sex- and age-
matched 860 AF-free control subjects with written informed
consent were genetically unrelated to the cases. They were
recruited from healthy subjects without individual history of AF
and other chronic diseases. All subjects were genetically unrelated
ethnic Han Chinese.
Among all the subjects, genotyping was failed in 20 cases
(2.59%) and 15 controls (1.88%) due to DNA quality or quantity.
Therefore, 840 lone AF cases and 845 healthy controls were finally
included in the susceptibility analyses. Among the 840 cases, 725
received first-time catheter ablation and were successfully
cardioverted to stable SR. During the follow-up, 112 patients
were lost and 3 cases died because trauma or cerebrovascular
accident. Therefore, a total of 610 patients had complete follow-
ups and clinical information.
2.3. Follow-Up
AF-free time was calculated from the date of ablation to the date
of recurrence or last follow-up. Atrial arrhythmias that occurred
during the first 2 months after ablation, which is considered a
blanking period [12], were not counted as recurrences. Antiar-
rhythmic medications, including amiodarone, metoprolol or
propafenone, were generally continued to the end of third month
after ablation unless recurrent arrhythmia indicated the need for
continued treatment. All patients with documented arrhythmia
and those maintained on antiarrhythmics for control of AF beyond
the blanking period were counted as recurrences.
Patients had scheduled clinical visits, 12-lead ECG, and 24-hour
Holter monitoring at 3, 6, and 12 months after ablation and then
yearly after the first year. Moreover, patients would receive ECG
monitoring in local clinics at anytime if they had AF-related
symptoms. AF recurrence was identified by symptoms with ECG
documentation of an atrial tachyarrhythmia lasting $30 seconds
on a 12-lead ECG or Holter monitor recording. AF recurrence
during the follow-up was considered censored.
2.4. Genotyping
Genomic DNA was isolated from leukocytes of venous blood by
proteinase K digestion and phenol/chloroform extraction. The
Table 1. Baseline characteristics of subjects with LAF and controls.
Variables
LAF
group Control group p-value
Patient number (n) 840 845 -
Sex, M/F (n) 561/279 562/283 0.904
Age at enrollment (yrs) 52.8610.9 52.8614.9 0.938
Age at first diagnosis of AF (yrs) 45.6611.3 N/A -
Paroxysmal/Persistent AF (n) 592/248 N/A -
Body mass index (kg/m2) 23.862.9 23.963.0 0.501
Cigarette smoking (n) 138 168 0.066
Alcohol intake .= 1 drink per day (n) 98 96 0.844
Hypercholesterolaemia (n) 46 65 0.067
Left atrial dimension (mm) 39.166.7 31.163.6 ,0.001
Medications before enrollment (n)
Digitalis 90 N/A -
Propafenone 135 N/A -
Amiodarone 155 N/A -
Beta-blocker 258 N/A -
ACE-I/ARB 171 N/A -
Calcium-channel blocker 50 N/A -
Warfarin 311 N/A -
Statins 20 N/A -
Values are presented as mean6SD or number of patients.
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
doi:10.1371/journal.pone.0112912.t001
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TGF-b1 C-509T polymorphism was determined using the PCR–
restriction fragment length polymorphism method. The PCR
primers for the TGF-b1 C-509T polymorphism were 59-
GCTAAGGCATGGCACCGCTT-39 (forward) and 59-GAAG-
GAGGGTCTGTCAACATGGG-39 (reverse). PCR was per-
formed in a total volume of 20 mL containing 50 ng genomic
DNA, 106Taq buffer, 0.02 mmol?L21 of MgCl2, 0.05 mmol?L
21
of dNTP mix, 10 pmol?mL21 of each primer and 1 U Taq DNA
polymerase. After initial denaturation at 95uC for 5 minutes, the
reaction was carried out at 95uC denaturation for 30 seconds,
annealing for 40 seconds at 62uC and extension for 45 seconds at
72uC for a total of 34 cycles, and a final elongation at 72uC for
10 minutes. The 270-bp PCR products were digested by the
restriction enzyme (Eco81I, SauI) (MBI Fermentas, Vilnius,
Lithuania) at 37uC overnight. The digested products were then
analyzed by electrophoresis in 3% agarose gel stained with 0.5%
ethidium bromide and photographed under UV illumination. The
C allele was cut into 198-bp and 72-bp fragments, whereas the T
allele was not digested. The polymorphism analysis was carried
out by two persons independently in a blinded manner. More than
15% of the samples were randomly selected for confirmation, and
the results were 100% concordant.
2.5. LAA samples
In order to determine the expression of TGF-b1 and interstitial
fibrosis, we collected 24 LAA tissues from healthy heart donors for
transplantation. They were trauma victims and were free of
cardiovascular pathology and documented AF. LAA specimens
were obtained before perfusion. A part of each LAA was fixed in
paraformaldehyde for histology, and the others were immediately
snap-frozen in liquid nitrogen for laboratory analysis.
2.6. Real-time quantitative RT-PCR
The primers of TGF-b1 (Forward primer [F]: 59-
CTAATGGTGGAAACCCACAACG-39, Reverse primer [R]:
59-TATCGCCAGGAATTGTTGCTG-39, NM_000660) and
glyceraldehydes 3-phosphate dehydrogenase (GAPDH) (Forward
primer [F]: 59-ATGGGGAAGGTGAAGGTCG-39, Reverse
primer [R]: 59-GGGGTCATTGATGGCAACAATA-39,
NM_002046) were synthesized by Invitrogen Co., Hong Kong,
China. Total RNA was isolated from frozen RAAs by acid-phenol
extraction in the presence of chaotropic salts (TRIzol, Invitrogen)
and subsequent isopropanol ethanol precipitation. The synthesis of
cDNA was according to the manufacturer’s instructions with the
reverse transcriptase kit (Promega Co., US). The real-time PCR
was performed using the LightCycler 480 system (Roche
Diagnostics, Switzerland) with a total volume of 20 ml containing
10 ml 26Master Mix SYBR Green I (Takara, Japan), 0.25 mM
forward primers, 0.25 mM reverse primers, 2 ml cDNA template,
and H2O to a final volume of 20 ml. The protocol of real-time
PCR consisted of 40 cycles, and cycling parameters were as
follows: denaturation at 94uC for 10 seconds, annealing at 61uC
for 15 seconds and extension at 72uC for 20 seconds. The results
were analyzed using Roche LightCycler 480 software. Data of
transcripts were calculated relative to GAPDH using the 22DDCt
method. The measurements of each sample were performed in
triplicate.
2.7. Western blot
Frozen LAAs were used for protein isolation as described
previously [13]. Proteins (40 mg/lane) were separated by sodium
dodecyl sulfate polyacrylamide gel electropheresis and transferred
onto Polylinylidene Fluoride membranes using a Bio-Rad semidry
transfer system (Bio-Rad). The membranes were blocked with 5%
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Table 3. Results of Cox multivariate regression analysis on cumulative AF recurrence after catheter ablation.
Final variables b SEM HR 95% CI p-value
Hypertension at enrollment 0.289 0.159 1.335 0.977–1.824 0.070
Persistent AF 1.456 0.147 4.289 3.217–5.718 ,0.001
Postoperative Statins –0.211 0.145 0.810 0.610–1.076 0.146
Left atrial dimension 1.651 0.143 5.212 3.937–6.900 ,0.001
C-509T (CT/TT vs. CC) 1.416 0.236 4.121 2.597–6.539 ,0.001
b, regression coefficient; HR, hazard ratio.
doi:10.1371/journal.pone.0112912.t003
Figure 1. Kaplan-Meier survival curves showing freedom from AF recurrence after catheter ablation according to TGF-b1 C-509T
polymorphism. (A) Survival free from AF recurrence in CC (n = 120), CT (n = 231) and TT (n = 259) groups. (B) Survival free from AF recurrence in CC
(n = 120) and CT/TT (n = 490) groups.
doi:10.1371/journal.pone.0112912.g001
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non-fat dry milk and then probed with mouse monoclonal TGF-
b1 (ab27969, Abcam, USA) and horseradish peroxidase (HRP)-
conjugated mouse monoclonal anti-GAPDH (KC-5G5, Kang-
Chen Biotech, China). The working dilutions were 1:2000 (TGF-
b1) and 1:5000 (GAPDH). The resulting reaction was visualized
using HRP-conjugated anti-mouse secondary antibody (Santa-
Cruz Biotechnology, the Netherlands), followed by incubation
with ECL Western Blot Detection Kit (Amersham, the Nether-
lands) for 1 minute. The blots were exposed to Kodak film for
5 minutes and immunoreactive bands developed for quantification
using The Discovery Series image analysis software (Bio-Rad)
normalized by the corresponding value of GAPDH. Experiments
were repeated three times and the mean was scored.
2.8. Masson’s trichrome staining
After fixation with 4% paraformaldehyde in phosphate-buffered
saline (PH: 7.4) for 24 h, the tissues were subjected to alcoholic
dehydration and embedded in paraffin. 4 mm serial sections were
sliced and subjected to Masson’s trichrome staining to highlight
collagen fibers. Collagen volume fraction (CVF) was determined
by the HPISA 100 chromatic color pathological analysis system
(Olympus, Japan) using five random images from each slide and
five slides per sample, and the mean values of CVF were obtained
by one investigator blinded to the groups.
2.9. Promoter functional assay
The isolation and culture of mouse atrial fibroblasts were
previously described [14]. The TGF-b1 promoter-luciferase
reporter plasmids containing either -509C or -509T sequences
were prepared by amplifying the 270-bp TGF-b1 promoter region
by using primers with restriction sites. The primers were 59-
GCTAAGGCATGGCACCGCTT-39 (forward) and 59-GAAG-
GAGGGTCTGTCAACATGGG-39 (reverse), including the KpnI
and XhoI restriction sites. The amplified fragments were then
sequenced to confirm that there were no errors in matched
nucleotides and the plasmid encompassed either -509C or -509T
allele. The amplified fragments and luciferase reporter vectors
(pGL3)-basic vector (Promega, Madison, WI, USA) were cleaved
by using the KpnI and XhoI enzymes (Promega, USA), and the
fragments were then cloned into the pGL3-basic vector. After
cloning, the vectors were sequenced to confirm the orientation and
integrity of the inserts of each construct. For transfections, mouse
atrial fibroblasts were seeded onto 24-well plates (100,000 cells per
well), and each well was transfected with 1 mg of the vector DNA
with either -509C or -509T allele, using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA). As an internal standard, all
plasmids were cotransfected with 8 ng pRL-SV40, which
contained the Renilla luciferase gene. The pGL3-basic vector
without an insert was used as a negative control. After 48 hours of
Figure 2. Effect of the C-509 T polymorphism in the TGF-b1
promoter activity. (A) Schematic representation of reporter plasmids
containing the -509C or -509 T allele, which was inserted upstream of
the luciferase reporter gene in the pGL3 basic plasmid. (B) Two
constructs were transiently transfected into the mouse cardiac
fibroblasts. The luciferase activity of each construct was normalized
against the internal control of Renilla luciferase (blank). Values are
mean6SD.
doi:10.1371/journal.pone.0112912.g002
Figure 3. Atrial expression of TGF-b1 among different geno-
types in healthy heart donors. (A) Representative Western
immunoblots. (B) Gene expression in left atrial appendages (LAAs). (C)
Semi-quantitative protein content in LAAs. Boxes show interquartile
ranges, and bars represent the 10th and 90th percentiles.
doi:10.1371/journal.pone.0112912.g003
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incubation, cells were collected and analyzed for luciferase activity
with the Dual-Luciferase Reporter Assay System (Promega,
Madison, WI, USA).
2.10. Statistical analysis
Differences in the distributions of demographic characteristics,
clinical variables, and frequencies of genotypes of TGF-b1 C-
509T polymorphism between the cases and controls were
evaluated using the Student’s t-test (for continuous variables) and
x2 test (for categorical variables). Hardy–Weinberg equilibrium
Figure 4. Representative photomicrographs of Masson staining showing the interstitial collagen (stained blue) (6200, bar=50 mm).
Collagen volume fraction is used to evaluate the degree of fibrosis.
doi:10.1371/journal.pone.0112912.g004
Figure 5. Correlation between atrial protein expression of TGF-b1 and collagen volume fraction in LAAs.
doi:10.1371/journal.pone.0112912.g005
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was tested using a goodness-of-fit x2 test. The association between
the TGF-b1 C-509T polymorphism and AF risk was estimated by
computing odds ratios (ORs) and their 95% confidential intervals
(CIs) from multivariate logistic model. An allele-specific difference
in luciferase activity was also tested using the Student’s t-test. For
the comparison of atrial expression of TGF-b1 and the degree of
atrial fibrosis, one-way ANOVA test (normally distributed) or
Mann-Whitney test (2 groups, non-normally distributed) and
Kruskal-Wallis test (n groups, non-normally distributed) were used
among the three genotypes. Spearman correlation analysis was
applied to assess the association between expression of TGF-b1
and CVF in LAAs. The Kaplan-Meier method, log-rank test, and
Cox survival regression model were used to determine factors
predictive of AF outcome after ablation. p,0.05 was considered
statistically significant, and all statistical tests were two-sided. All
the statistical analyses were performed with Statistical Analysis
System software (v.9.1.3; SAS Institute, Cary, NC, USA).
Results
3.1. Characteristics of the study population
The characteristics of LAF group and Control group enrolled in
this study were shown in Table 1. There were no significant
differences in the distribution of the age, sex, body mass index
(BMI), cigarette smoking, alcohol intake and hypercholesterolae-
mia. Left atrial dimension (LAD) was significantly lager in LAF
than control. In LAF group, age at first diagnosis of AF was
45.6611.3 years, and 70.5% was paroxysmal AF. Medications
before enrollment in LAF group were Digitalis (n = 90), Propafe-
none (n= 135), Amiodarone (n= 155), Beta-blocker (n = 258),
angiotensin-converting enzyme inhibitor/angiotensin receptor
blocker (n = 171), Calcium-channel blocker (n = 50), Warfarin
(n = 311) and Statins (n = 20).
3.2. TGF-b1 C-509T polymorphism and LAF risk
The genotype and allele distributions of the TGF-b1 C-509T
polymorphism in the cases and controls are shown in Table 2. The
observed genotype frequencies for this polymorphism were in
Hardy–Weinberg equilibrium in the controls (x2=0.286,
p=0.593). The frequencies of the CC, CT and TT genotypes
were 18.1%, 40.2% and 41.7%, respectively, among the cases, and
32.3%, 47.8% and 19.9%, respectively, among the controls. After
adjusting for possible confounders (age, sex, body mass index,
smoking status, drinking status, and hypercholesteremia), subjects
carrying CT or TT or CT/TT genotypes had an increased risk of
LAF (adjusted OR=1.50(1.17–1.92) for CT, 3.72 (2.83–4.88) for
TT and 2.15 (1.71–2.70) for CT/TT; ptrend,0.001), compared
with CC homozygote, and the frequency of the T allele being
higher than C allele among LAF subjects (p,0.001).
3.3. Factors associated with AF recurrence after ablation
Over a median follow-up of 17.5 months (range, 3.5 to n 71
months) after ablation, 207 patients (33.9%) had AF recurrence
and 403 patients (66.1%) remained in SR. I multivariate Cox
proportional hazards analysis, factors associated with arrhythmia
recurrence were found to be persistent AF (versus paroxysmal AF;
HR=4.289 (3.217–5.718); p,0.001), larger left atrial dimension
(HR=5.212 (3.937–6.900); p,0.001), CT/TT genotype (versus
CC genotype; HR=4.121 (2.597–6.539); p,0.001) (Table 3). In
addition, Kaplan-Meier survival estimates showed that LAF
patients carrying different TGF-b1 C-509T genotypes had
different proportion of AF recurrence (p,0.001) (Figure 1A).
Moreover, CT/TT genotypes also had a higher proportion of AF
recurrence after ablation, compared with CC genotype (p,0.001)
(Figure 1B).
3.4. TGF-b1 C-509T polymorphism and luciferase activity
As shown in Figure 2, the vector with the -509T allele had an
increase in the relative luciferase activity, compared with that with
the -509C allele (p,0.01). These results suggested that the -509T
allele may lead to a higher expression levels of TGF-b1 mRNA
than the -509C allele.
3.5. Expression of TGF-b1 and the degree of atrial fibrosis
among genotypes
In the 24 LAA specimens, 7 were of the CC genotype, 9 of the
CT genotype, and 8 of the TT genotype. As shown in Figure 3B,
Real-time quantitative RT-PCR assay showed an increasing
gradient of gene expression of TGF-b1 in the groups carrying
CC, CT and TT genotypes, although there was merely a
borderline significant difference between CC and CT groups
(p=0.057).
Western blot analysis (Figure 3A, C) showed an increased
expression of TGF-b1 in CT and TT groups than CC group,
whereas the difference was borderline between CT and TT groups
(p=0.058).
Interstitial collagen (stained blue), revealed by Masson staining
and expressed as CVF, was lowest in CC group, followed by CT
and TT groups (Figure 4). However, there was merely a
borderline significant difference between CT and TT groups
(p=0.054).
The correlation test indicated a strong positive correlation
between atrial protein expression of TGF-b1 and CVF in LAAs
(r = 0.695, p,0.001; Figure 5).
Discussion
In this case-control study, we investigated the relationships
between TGF-b1 C-509T polymorphism and susceptibility and
prognosis of LAF in Chinese population. We made several new
findings. First, our results revealed that the CT and/or TT
genotypes had an increased LAF risk [adjusted OR=1.50 for CT,
OR=3.72 for TT, and OR=2.15 for CT/TT], compared with
the TGF-b1CC genotype. Second, we demonstrated that LAF
patients carrying CT/TT genotypes had a higher possibility of AF
recurrence after ablation, compared with patients carrying CC
genotype. Furthermore, we validated both in vitro and vivo that T
allele had higher expression of TGF-b1 and more aggravated
atrial interstitial fibrosis than C allele. However, a recent study
determining the same polymorphism in also Chinese Han
population found no association between the rs1800469 polymor-
phism and the risk of AF under the dominant, recessive and
additive genetic models [15]. It could be due to their enrolled
patients who had kinds of underlying disease (hypertension,
coronary heart disease and so on) and were much older. But
herein we only recruited LAF cases who were probably
determined by genetics. Moreover, they had much fewer cases.
So the inherent selection bias could not be completely excluded.
To the best of our knowledge, this is the first study to investigate
the potential functional polymorphism C-509T of TGFb-1
promoter in susceptibility and prognosis of AF.
Currently, atrial remodeling has been demonstrated as the most
important pathophysiological mechanism of AF. Electrical remod-
eling is reversible, but in patients with a long history of AF or
severe comorbidities, structural remodeling has become severe and
irreversible, causing progression of AF and making it challenging
to restore and maintain SR [16]. Among atrial structural
A Polymorphism in TGFb-1 and Atrial Fibrillation
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remodeling including myolysis, apoptosis, fibrosis and inflamma-
tion, atrial interstitial fibrosis is the most important process in
development and progression of LAF [16]. TGF-b1 is a cytokine
that modulates the tissue fibrosis [4]. Recent studies showed that
over-expression of TGF-b1 as well as an increase of atrial fibrosis
was observed in atrial specimens from patients with AF [17–19].
High-expression of atrial TGF-b1 indicated a higher recurrence
rate and a poor recovery of atrial mechanical contraction after
surgical maze procedure [20–21]. It was speculated and further
confirmed in an transgenic animal model that atrial over-
expression of TGF-b1 selectively induced atrial interstitial fibrosis,
contributing to AF vulnerability [5,19]. Inhibition of TGF-b1
expression by an antiallergic drug named Tranilast decreased the
atrial fibrosis and AF vulnerability [22]. These studies suggest that
the TGF-b1 attributes to development and recurrence of AF via
triggering atrial fibrosis.
The human TGF-b1 gene is located on chromosome 19q13 and
can be transcribed and translated to form a 390 amino acid
propeptide. The C-509T polymorphism of TGF-b1 gene is
located in the promoter region which is relative to the first major
transcription start site and was found to be related to transcrip-
tional activity and plasma concentration of TGF-b1 [23]. A recent
study firstly investigated the polymorphisms of TGF-b1 T +869C
at codon 10 and G +915C at codon 25 in susceptibility of AF in
essential hypertensive subjects, and found the latter was associated
with occurrence of AF and serum TGF-b1 level in this population
[24]. In this study, our results suggested that the -509T allele
leaded to a higher expression level of TGF-b1 both in vivo and
in vitro correlated with more severe interstitial fibrosis. Therefore,
it is suggested that increased TGF-b1 expression by -509T allele
may induce overproduction of extracellular matrix components
such as collagen by myofibroblasts, resulting in progressive atrial
augmentation, fibrosis, and probably the susceptibility and
recurrence of LAF. It is further speculated that TGF-b1 gene
polymorphisms could regulate expression of TGF-b1 and play a
role in the development and prognosis of LAF.
According to recent guidelines, catheter ablation is considered
as initial therapy in selected patients, especially in those with
symptomatic paroxysmal AF with no or minimal heart disease and
those failed to antiarrhythmic drug therapy [25]. So it is very
important to evaluate the prognosis of LAF after catheter ablation.
The previous studies demonstrated that bigger left atrial dimen-
sion and persistent AF significantly increased the risk of recurrent
after ablation [26–28], which was consistent with our findings.
Interestingly, we found that TGF-b1 C-509T polymorphism could
also be an independent predictor of recurrence after AF ablation
in LAF patients. Patients carrying CT/TT genotypes may have
higher atrial expression of TGF-b1 as well as more severe atrial
interstitial fibrosis, therefore may be not the suitable candidate for
isolated catheter ablation.
4.1. Clinical perspectives
Atrial structural remodeling, particularly interstitial fibrosis,
limits the efficacy of existing therapies for AF in clinic.
Accordingly, attenuation of structural remodeling, so-called
upstream therapy, has increasingly become the focus of attention.
It can prevent both the development of AF (primary prevention)
and AF recurrence after cardioversion (secondary prevention),
therefore becomes a promising approach for AF treatment [29].
Previously, it had been demonstrated that TGF-b1 neutralization
via polyclonal antibodies could result in the down-regulation of
extracellular matrix gene expression in rats [30]. Likewise,
regulating excessive expression of endogenic TGF-b1 may also
help to prevent fibrosis in atria. Taken together, we propose that
inhibiting excessive expression of endogenic TGF-b1 by targeting
the TGF-b1 C-509T polymorphism can be a new promising
upstream therapy of AF. Additionally, profile evaluation of TGF-
b1 gene polymorphisms has the potential to be used clinically as a
routine pre-ablation assessment, and together with other factors
including AF type and left atrial diameter, may provide a more
integrated picture for physicians to evaluate the clinical status of
LAF patients. Paroxysmal AF patients carrying CC genotype of
TGF-b1 C-509T polymorphism without significantly enlarged left
atria may be the optimal candidates for catheter ablation.
4.2. Limitations
Firstly, although 24 LAA specimens were statistically large
enough to support our findings, the small sample size indeed
limited the statistical power. Secondly, despite regular screening of
patients with outpatient visits and ambulatory ECG monitoring,
the detection of all episodes of AF recurrence, particularly
asymptomatic ones, is very difficult to establish. Therefore, we
may have underestimated the true incidence of AF recurrence in
our study. Finally, although we applied a rigorous epidemiological
design in selecting study subjects and adjusted for confounding
factors in further statistical analysis to minimize the potential
biases, inherent selection bias cannot be completely excluded.
Conclusion
Our study showed that the TGF-b1 C-509T polymorphism was
associated with LAF risk and AF recurrence after catheter ablation
by affecting the expression level of TGF-b1 as well as the degree of
atrial interstitial fibrosis. These findings enhanced our knowledge
of the role of TGF-b1 in AF, and suggested that the C-509T
polymorphism could be a functional genetic target for developing
new treatment strategies and guide the physicians for catheter
ablation as a useful marker.
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